Literature DB >> 2250764

Effect of endothelin-1, endothelin-3 and C-terminal hexapeptide, endothelin (16-21) on motor activity in rats.

A Lecci1, C A Maggi, P Rovero, A Giachetti, A Meli.   

Abstract

Intracerebroventricular administration of ET-1 (12.5 and 25 pmol/rat) and ET-3 (25 and 50 pmol/rat) induced the loss of the righting reflex and barrel-rolling behaviour in rats. The C-terminal hexapeptide ET(16-21) did not produce these effects. The automated recording of motor activity revealed that, unlike ET (16-21), both ET-1 and ET-3 evoke a dose-regulated increase of the immobility time. Pretreatment with peptidase inhibitors did not modify the activity of subthreshold doses of peptides. Since ET (16-21) display full agonist properties at ETB but does not interact with ETA receptors, the present data suggest that the behavioural syndrome induced by centrally administered ET-1 and ET-3 may be mediated by stimulation of ETA receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2250764     DOI: 10.1016/0143-4179(90)90025-t

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Metabolic and neuroanatomical correlates of barrel-rolling and oculoclonic convulsions induced by intraventricular endothelin-1: a novel peptidergic signaling mechanism in visuovestibular and oculomotor regulation?

Authors:  P M Gross; R J Beninger; S W Shaver; D S Wainman; F J Espinosa; D F Weaver
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

2.  Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA.

Authors:  T D Warner; G P Budzik; T Matsumoto; J A Mitchell; U Förstermann; F Murad
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

3.  Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA.

Authors:  T D Warner; H H Schmidt; J Kuk; J A Mitchell; F Murad
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.